Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$685 Mln
P/E Ratio
--
P/B Ratio
1.36
Industry P/E
--
Debt to Equity
0.01
ROE
-0.22 %
ROCE
-22.41 %
Div. Yield
0 %
Book Value
5.41
EPS
-1.03
CFO
$-323.27 Mln
EBITDA
$-453.17 Mln
Net Profit
$-446.75 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Day One Biopharmaceuticals Inc (DAWN)
| -46.01 | -15.76 | -44.84 | -53.18 | -15.46 | -- | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Day One Biopharmaceuticals Inc (DAWN)
| -13.12 | -32.16 | 27.72 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral... brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California. Address: 1800 Sierra Point Parkway, Brisbane, CA, United States, 94005 Read more
CEO, President & Director
Dr. Jeremy Bender M.B.A., Ph.D.
CEO, President & Director
Dr. Jeremy Bender M.B.A., Ph.D.
Headquarters
Brisbane, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Day One Biopharmaceuticals Inc (DAWN) stood at $ 583 Mln as on 31-Dec-24
The share price of Day One Biopharmaceuticals Inc (DAWN) is $6.84 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Day One Biopharmaceuticals Inc (DAWN) has given a return of -15.46% in the last 3 years.
Day One Biopharmaceuticals Inc (DAWN) has a market capitalisation of $ 685 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Day One Biopharmaceuticals Inc (DAWN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Day One Biopharmaceuticals Inc (DAWN) and enter the required number of quantities and click on buy to purchase the shares of Day One Biopharmaceuticals Inc (DAWN).
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California. Address: 1800 Sierra Point Parkway, Brisbane, CA, United States, 94005
The CEO & director of Dr. Jeremy Bender M.B.A., Ph.D.. is Day One Biopharmaceuticals Inc (DAWN), and CFO & Sr. VP is Dr. Jeremy Bender M.B.A., Ph.D..
There is no promoter pledging in Day One Biopharmaceuticals Inc (DAWN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Day One Biopharmaceuticals Inc (DAWN) | Ratios |
|---|---|
|
Return on equity(%)
|
-22.49
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-72.81
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Day One Biopharmaceuticals Inc (DAWN) was $0 Mln.
$0.08
(
